DUBAI, Arab Emirates, January 21, 2022 (Newswire.com) - AiPharma, a global biopharmaceutical company developing and commercializing innovative antiviral therapies, has completed an extensive rebranding effort in response to accelerated company growth and to reflect the business's expanded strategy. The company has undergone a significant transformation at the beginning of 2022 and has decided to relaunch its business under the new brand name Cellvera.
The name Cellvera, originated from Latin, breaks down to 'cell' - which is referred to as the smallest yet fundamental unit of life in which the DNA code is being stored, and 'vera' which means true. This name represents the company and aligns with its beliefs and approach towards the science in which lies the truth of life and health encoded in the DNA.
This transformation is the result of a redefined strategy that in addition to Cellvera's exiting flagship, the antiviral portfolio expands its focus on diversified, highly innovative therapies and other treatment solutions for rare and difficult-to-treat illnesses.
Driven by the confidence that medicine's most significant discoveries lie ahead and are now within reach, Cellvera aims to build a strong footprint in the space of virology, immunology, precision medication, and genetics, improving the lives of patients worldwide.
Cellvera represents the company's ambition to accelerate life science research and development in the pursuit of improved human health. It aspires to be at the forefront of pioneering integrated Artificial Intelligence discovery, manufacturing, and distribution platforms in bioscience to support public health globally.
The first step towards achieving Cellvera's expanded strategic goals is materialized by the appointment of Dr. Ashraf Allam as Executive Chairman.
Dr. Allam has more than 30 years of experience in the life science industry across the globe. He served as the CEO of the Pharmaceutical Investment Company, which is wholly owned by the (KSA) Kingdom of Saudi Arabia Public Investment Fund (PIF), a global investment powerhouse and one of the most significant sovereign wealth funds in the world, with assets of more than $500 billion. Before that, Ashraf held several executive regional and global roles in large multinationals, in both listed and privately-owned companies, including Mundipharma, Amgen, Johnson & Johnson, Eli Lilly & Company, and Bristol Myers Squibb; he played a strategic role in setting up and managing their business.
Alessandro Gadotti, CEO of Cellvera, said: "This is a very exciting time for the Cellvera team, and with Ashraf on board, I am confidently looking forward to achieving our goals and fulfilling the vision of building a robust global biopharma powerhouse ready to take the healthcare to another level. I strongly believe this is possible to achieve through the combination of science, AI, and digital diagnostics and technology, as well as through the unique partnerships with the top-tier allies pioneering the healthcare solutions of the new era."
In addition to strategy evolution and strengthening Cellvera's global presence, the company emphasizes the need for further geographic expansion to provide more patients worldwide with access to novel medical treatments based on their needs. "This is very important as the ongoing pandemic exposed serious healthcare challenges for many patients who were or still cannot obtain the adequate treatment preventing or treating them for Covid-19 disease," added Gadotti.
Cellvera is committed to providing patients with effective antiviral solutions against SARS-CoV-2 and other viruses and will continue working with their existing and future partners to accomplish this.
Cellvera is a global biopharmaceutical company focused on discovering, developing, and commercializing diversified, highly innovative therapies and other treatment solutions for rare and difficult to treat illnesses.
Leveraging the company's deep understanding of antiviral drug development, nucleotide, biochemistry, and virology Cellvera accelerates life science research and development in the pursuit of improved human health. Cellvera's ambition is to be at the forefront of pioneering integrated Artificial Intelligence discovery, manufacturing, and distribution platforms in bioscience, virology, immunology, precision medication, and genetics to support public health globally.
Currently, Cellvera is focused on the clinical and commercial development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).